| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 6e-05 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.15 | 6e-05 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.14 | 7e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.21 | 0.0001 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |